Gynecological Cancer as a Second Malignancy in Patients With Breast Cancer

被引:13
作者
Yadav, Budhi Singh [1 ]
Sharma, Suresh C. [1 ]
Patel, Firuza D. [1 ]
Rai, Bhavana [1 ]
Ghoshal, Sushmita [1 ]
机构
[1] Post Grad Inst Med Educ & Res, Dept Radiat Oncol, Reg Canc Ctr, Chandigarh, India
关键词
Breast cancer; Second malignancy; Gynecological cancer; ADJUVANT TAMOXIFEN THERAPY; ENDOMETRIAL CANCER; OVARIAN-CANCER; CONSERVATIVE SURGERY; RADIATION-THERAPY; WOMEN; RISK; MANAGEMENT; DIAGNOSIS; MORTALITY;
D O I
10.1097/IGC.0000000000000993
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: The aim of this study was to determine the incidence and risk factors for gynecological cancer as second malignancy (SM) after treatment of breast cancer (BC). Methods and Materials: Between January 1985 and December 2007, a total of 2756 patients with BC were analyzed for gynecological cancers as an SM. Analysis was carried out for patient-, disease-, and treatment-related characteristics. The Cox proportional hazards regression model was used to estimate the relative risk of gynecologic malignancies. Results: The median age at BC diagnosis was 49 years and median follow-up of 14 years. In total, 25 cases of gynecological cancer were noted with an incidence of 0.9%. We observed 9 ovarian and endometrium (0.3%) as well as 7 uterine cervix (0.25%) cancers. Family history of BC was the most significant risk factor for SM(relative risk, 7.4; 95% confidence interval, 3.03Y18.28; P<0.001). Women with a family history of BC had a higher incidence of endometrial (12%) and ovarian (16%) cancer compared with those who have no family history (0.1%, P = 0.003). Statistically significant higher incidence of endometrial cancer was seen in patients undergoing hormonal therapy (0.4%) as compared with those who are not undergoing hormonal therapy (0.1%, P = 0.001). Most of the endometrial (88.9%) and cervical (71%) cancers were detected at an early stage but ovarian cancers (66.6%) in advanced stage. Chemotherapy and radiotherapy did not increase the risk of gynecological SM. Conclusions: Women with BC are at risk of developing a second primary gynecological malignancy particularly of endometrium and ovary. Family history of BC was a high risk factor for gynecologic SM. These patients should be followed up for its early detection.
引用
收藏
页码:1298 / 1304
页数:7
相关论文
共 41 条
[1]  
[Anonymous], 2009, Obstet Gynecol, V113, P957, DOI 10.1097/AOG.0b013e3181a106d4
[2]   EUSOMA guidelines on the management of familial breast cancer risk [J].
Blamey, R. W. ;
Mackay, J. ;
Macmillan, D. .
EJC SUPPLEMENTS, 2004, 2 (03) :155-155
[3]   2ND PRIMARY NEOPLASMS FOLLOWING BREAST-CANCER IN SAARLAND, GERMANY, 1968-1987 [J].
BRENNER, H ;
SIEGLE, S ;
STEGMAIER, C ;
ZIEGLER, H .
EUROPEAN JOURNAL OF CANCER, 1993, 29A (10) :1410-1414
[4]  
Brinton L., 2002, Cancer of the Breast, V5th, P111
[5]  
Brinton L.A., 2005, PRINCIPLES PRACTICE, P3
[6]   Effect of Screening on Ovarian Cancer Mortality The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial [J].
Buys, Saundra S. ;
Partridge, Edward ;
Black, Amanda ;
Johnson, Christine C. ;
Lamerato, Lois ;
Isaacs, Claudine ;
Reding, Douglas J. ;
Greenlee, Robert T. ;
Yokochi, Lance A. ;
Kessel, Bruce ;
Crawford, E. David ;
Church, Timothy R. ;
Andriole, Gerald L. ;
Weissfeld, Joel L. ;
Fouad, Mona N. ;
Chia, David ;
O'Brien, Barbara ;
Ragard, Lawrence R. ;
Clapp, Jonathan D. ;
Rathmell, Joshua M. ;
Riley, Thomas L. ;
Hartge, Patricia ;
Pinsky, Paul F. ;
Zhu, Claire S. ;
Izmirlian, Grant ;
Kramer, Barnett S. ;
Miller, Anthony B. ;
Xu, Jian-Lun ;
Prorok, Philip C. ;
Gohagan, John K. ;
Berg, Christine D. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2011, 305 (22) :2295-2303
[7]  
Clarke M, 1998, LANCET, V351, P1451
[8]   Incidence of second cancer within 5 years of diagnosis of a breast, prostate or colorectal cancer: a population-based study [J].
Cluze, Camille ;
Delafosse, Patricia ;
Seigneurin, Arnaud ;
Colonna, Marc .
EUROPEAN JOURNAL OF CANCER PREVENTION, 2009, 18 (05) :343-348
[9]   Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial [J].
Davies, Christina ;
Pan, Hongchao ;
Godwin, Jon ;
Gray, Richard ;
Arriagada, Rodrigo ;
Raina, Vinod ;
Abraham, Mirta ;
Medeiros Alencar, Victor Hugo ;
Badran, Atef ;
Bonfill, Xavier ;
Bradbury, Joan ;
Clarke, Michael ;
Collins, Rory ;
Davis, Susan R. ;
Delmestri, Antonella ;
Forbes, John F. ;
Haddad, Peiman ;
Hou, Ming-Feng ;
Inbar, Moshe ;
Khaled, Hussein ;
Kielanowska, Joanna ;
Kwan, Wing-Hong ;
Mathew, Beela S. ;
Mittra, Indraneel ;
Mueller, Bettina ;
Nicolucci, Antonio ;
Peralta, Octavio ;
Pernas, Fany ;
Petruzelka, Lubos ;
Pienkowski, Tadeusz ;
Radhika, Ramachandran ;
Rajan, Balakrishnan ;
Rubach, Maryna T. ;
Tort, Sera ;
Urrutia, Gerard ;
Valentini, Miriam ;
Wang, Yaochen ;
Peto, Richard .
LANCET, 2013, 381 (9869) :805-816
[10]   Common hereditary cancers and implications for primary care [J].
Emery, J ;
Lucassen, A ;
Murphy, M .
LANCET, 2001, 358 (9275) :56-63